"Current status of drug treatment against the disease caused by the Ebola virus/Situación actual del tratamiento farmacológico
frente a la enfermedad causada por el virus Ébola"
Elemento
Click for External Resource*
Click to read full article*
*The link above may share a zip file (.zip) hosted on repository.netecweb.org. Zip files will download automatically.
*All other links are external and will open in a new window. If you click an external link, you are leaving the NETEC site, and we do not maintain, review, or endorse these materials. See our terms of use.
Files for Download
reina19jan2016.pdf
Item Type
PublicaciónTerms of Use
By accessing these materials you are agreeing to our terms of use, which may be found here: Terms of Use.
Visor de documentos
Título
"Current status of drug treatment against the disease caused by the Ebola virus/Situación actual del tratamiento farmacológico
frente a la enfermedad causada por el virus Ébola"
frente a la enfermedad causada por el virus Ébola"
Materia
Descripción
The recent epidemic of disease caused by the Ebola virus has highlighted the need to develop specific drugs and have to deal with this entity.
Autor
Fecha
2016-02-01
Tipo
Citación
J. Reina. "[Current Status of Drug Treatment against the Disease Caused by the Ebola Virus]." Rev Esp Quimioter 29, no. 1 (Feb 2016): 1-7.
Resumen
La reciente epidemia de enfermedad causada por el virus Ébola ha puesto en evidencia la necesidad de desarrollar y disponer de fármacos específicos para hacer frente a esta entidad. De acuerdo con los datos virológicos se han diseñado algunos fármacos nuevos y se ha comprobado que otros podrían tener eficacia frente a este virus.
Las principales líneas terapéuticas se basan en la inmunoterapia (suero de pacientes convalescientes y anticuerpos monoclonales específicos), en fármacos antivirales (favipioravir, BCX4430, Brincidofovir), RNAs de interferencia (TKM-Ébola)y oligonucleótidos sin sentido (morfolino fosforodiamidato) y otros fármacos no antivirales (clomifeno, NSC62914, FGI-103, amilorida y la ouabaina).
Los estudios existentes son escasos y principalmente en modelos animales y los ensayos clínicos han quedado la ma-yoría inconclusos por la disminución drástica del número de nuevos casos.
A pesar de ello se ha avanzado en el conocimiento biológico del virus Ébola y se han localizado nuevas dianas terapéuticas para el futuro desarrollo de antivirales específicos.
The recent epidemic of disease caused by the Ebola virus has highlighted the need to develop specific drugs and have to deal with this entity. According to virological analysis they have been designed to give you some new drugs and are proven to others might be effective against this virus.
The main lines of therapy are based on immunotherapy (convalescent serum of patients and specific monoclonal antibodies), antiviral drugs (favipiravir, BCX4430, brincidofovir), interfering RNAs (TKM-Ebola) and antisense oligonucleotides (morpholino phosphorodiamidate) and other drugs no antiviral (clomiphene NSC62914, FGI-103, amiloride and ouabain).
Existing studies are scarce and mainly in animal models and clinical trials have been inconclusive most by the drastic reduction in the number of new cases.
However, progress has been made in the biological knowledge of Ebola virus and have been located new therapeutic targets for the future development of specific antiviral.
Las principales líneas terapéuticas se basan en la inmunoterapia (suero de pacientes convalescientes y anticuerpos monoclonales específicos), en fármacos antivirales (favipioravir, BCX4430, Brincidofovir), RNAs de interferencia (TKM-Ébola)y oligonucleótidos sin sentido (morfolino fosforodiamidato) y otros fármacos no antivirales (clomifeno, NSC62914, FGI-103, amilorida y la ouabaina).
Los estudios existentes son escasos y principalmente en modelos animales y los ensayos clínicos han quedado la ma-yoría inconclusos por la disminución drástica del número de nuevos casos.
A pesar de ello se ha avanzado en el conocimiento biológico del virus Ébola y se han localizado nuevas dianas terapéuticas para el futuro desarrollo de antivirales específicos.
The recent epidemic of disease caused by the Ebola virus has highlighted the need to develop specific drugs and have to deal with this entity. According to virological analysis they have been designed to give you some new drugs and are proven to others might be effective against this virus.
The main lines of therapy are based on immunotherapy (convalescent serum of patients and specific monoclonal antibodies), antiviral drugs (favipiravir, BCX4430, brincidofovir), interfering RNAs (TKM-Ebola) and antisense oligonucleotides (morpholino phosphorodiamidate) and other drugs no antiviral (clomiphene NSC62914, FGI-103, amiloride and ouabain).
Existing studies are scarce and mainly in animal models and clinical trials have been inconclusive most by the drastic reduction in the number of new cases.
However, progress has been made in the biological knowledge of Ebola virus and have been located new therapeutic targets for the future development of specific antiviral.
Accesibilidad
Free online, CC-BY-NC 4.0
Was this resource helpful?